Last reviewed · How we verify
Prevascar 25ng
Prevascar 25ng is a Small molecule drug developed by Renovo. It is currently in Phase 1 development.
Prevascar 25ng is a protein-based intervention that has been studied in clinical trials for its effects on scarring, cicatrix, and wound healing. The exact mechanism of Prevascar 25ng is not specified, but it is known to be a non-glycosylated form of IL-10, a protein involved in various biological processes.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Prevascar 25ng |
|---|---|
| Sponsor | Renovo |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Prevascar in African Continental Group Scarring (PHASE1)
- Investigation Into the Scar Reduction Potential of Prevascar (Interleukin-10) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevascar 25ng CI brief — competitive landscape report
- Prevascar 25ng updates RSS · CI watch RSS
- Renovo portfolio CI
Frequently asked questions about Prevascar 25ng
What is Prevascar 25ng?
Who makes Prevascar 25ng?
What development phase is Prevascar 25ng in?
Related
- Manufacturer: Renovo — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing